Abeona Therapeutics Inc
NASDAQ:ABEO

Watchlist Manager
Abeona Therapeutics Inc Logo
Abeona Therapeutics Inc
NASDAQ:ABEO
Watchlist
Price: 5.13 USD 5.34% Market Closed
Market Cap: 278m USD

Abeona Therapeutics Inc
Revenue

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Abeona Therapeutics Inc
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Abeona Therapeutics Inc
NASDAQ:ABEO
Revenue
$400k
CAGR 3-Years
-55%
CAGR 5-Years
-44%
CAGR 10-Years
-9%
Abbvie Inc
NYSE:ABBV
Revenue
$59.6B
CAGR 3-Years
1%
CAGR 5-Years
8%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Revenue
$29.1B
CAGR 3-Years
2%
CAGR 5-Years
5%
CAGR 10-Years
-1%
Amgen Inc
NASDAQ:AMGN
Revenue
$36B
CAGR 3-Years
11%
CAGR 5-Years
8%
CAGR 10-Years
5%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Revenue
$11.7B
CAGR 3-Years
10%
CAGR 5-Years
14%
CAGR 10-Years
31%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Revenue
$14.2B
CAGR 3-Years
1%
CAGR 5-Years
12%
CAGR 10-Years
14%
No Stocks Found

Abeona Therapeutics Inc
Glance View

Market Cap
268.8m USD
Industry
Biotechnology

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. The company is headquartered in New York City, New York and currently employs 90 full-time employees. The Company’s lead clinical programs consist of EB-101, which is an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102, which is an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101, which is an AAV-based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company is focused on to develop additional AAV-based gene therapies designed to treat ophthalmic and other diseases and AAV-based gene therapies using the AIM capsid platform that has a license from the University of North Carolina at Chapel Hill and internal AAV vector research programs.

ABEO Intrinsic Value
HIDDEN
Show

See Also

What is Abeona Therapeutics Inc's Revenue?
Revenue
400k USD

Based on the financial report for Sep 30, 2025, Abeona Therapeutics Inc's Revenue amounts to 400k USD.

What is Abeona Therapeutics Inc's Revenue growth rate?
Revenue CAGR 10Y
-9%

The average annual Revenue growth rates for Abeona Therapeutics Inc have been -55% over the past three years , -44% over the past five years , and -9% over the past ten years .

Back to Top